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 A data set has been developed for the reporting of
excisional biopsies and resection specimens for malignant
odontogenic tumors by members of an expert panel working
on behalf of the International Collaboration on Cancer
Reporting, an international organization established to unify
and standardize reporting of cancers. Odontogenic tumors
are rare, which limits evidence-based support for designing
a scientifically sound data set for reporting them. Thus, the
selection of reportable elements within the data set and
considering them as either core or noncore is principally
based on evidence from malignancies affecting other organ
systems, limited case series, expert opinions, and/or
anecdotal reports. Nevertheless, this data set serves as the
initial step toward standardized reporting on malignant
odontogenic tumors that should evolve over time as more
evidence becomes available and functions as a prompt for
further research to provide such evidence.
(Arch Pathol Lab Med. 2019;143:587–592; doi:
10.5858/arpa.2018-0417-SA)
As a starting point, an international panel of pathologistswith particular experience in the diagnosis and
management of malignant odontogenic tumors discussed
all issues considered significant in formulating a data set for
reporting these neoplasms. The panel was organized under
the auspices of the International Collaboration on Cancer
Reporting (ICCR), established in 2011 through a collabora-
tion between the College of American Pathologists, the
Canadian Association of Pathologists–Association Canadi-
enne des Pathologistes in association with the Canadian
Partnership Against Cancer, the Royal Colleges of Pathol-
ogists of Australasia and the United Kingdom, joined in
2013 by the European Society of Pathologists, and followed
by the American Society of Clinical Pathology and the Royal
College of Physicians of Ireland, Faculty of Pathology as
sustaining members. The members of the data set authoring
committee were nominated from the additional sponsoring
organizations: North American Society of Head and Neck
Pathology; American Academy of Oral and Maxillofacial
Pathology; the British Society for Oral and Maxillofacial
Pathology; and the International Association of Oral and
Maxillofacial Pathologists. Working via multiple teleconfer-
ences and reviewing a series of drafts that included many
comments and clarifications, the final data set contained
core and noncore elements.30 A core element (as defined by
the ICCR) represents an essential piece of information for
the management of the tumor, whereas a noncore element
constitutes an element that provides additional useful, but
not critical, information about the neoplasm. In some cases,
an element was designated noncore because the value was
not yet established but may be elevated to the status of a
core element in the future. Sometimes, elements can be
both. Because this group of tumors is rare, with only limited
prognostic data, selection of core and noncore elements was
principally based on basic oncologic principles applicable to
most malignant tumors and not necessarily on data
specifically derived from studies of large prospective cohorts
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of malignant odontogenic tumors. In this way, the policy of
the ICCR was implemented, namely, that generic descrip-
tors that apply to all cancer types should be included in data
sets irrespective of the level of evidence in the literature to
support their inclusion. Hopefully, in due time, higher levels
of evidence may be achieved. Currently, the level of




Specimens Submitted.—As for all pathology specimens,
the kind of specimen should be listed, including debulking
or curettage, excisional or incisional biopsy, and surgical
resection. Not specified is used only in rare instances and is to
be discouraged. Instead, there should be active personal
communication with the treating physicians to obtain the
required information. In case of a resection, appropriate and
concise terms to be used would be mandibulectomy or
maxillectomy with a prefix indicating the extent (hemi-,
partial, or total). In case of a neck dissection submitted
together with a tumor specimen, a separate, linked data set
for Nodal Excisions and Neck Dissection Specimens for Head &
Neck Tumours31 would be used to describe the neck lymph
node findings.
Tumor Site.—The tumor site belongs to standard items
listed in agreement with general rules regarding pathology
reports, irrespective of the kind of lesion. Giving the exact
anatomic site of involvement is most helpful, a finding that
may require correlation with clinical and imaging findings.
Tumor Dimensions (Core and Noncore).—Owing to
the intraosseous nature of odontogenic lesions, reference to
any imaging studies or consultation with a radiologist is
recommended in order to achieve the best interpretation of
maximum tumor dimension, combining macroscopy, spec-
imen or clinical radiology, and microscopy. Size criteria for
Figure 1. Ameloblastic carcinoma showing the pattern of ameloblastoma but also cytonuclear atypia, which allows for the distinction between the
entities (hematoxylin-eosin, original magnification3400).
Figure 2. Area of necrosis in spindle cell–type ameloblastic carcinoma (hematoxylin-eosin, original magnification3150).
Figure 3. Histology of sclerosing odontogenic carcinoma: inconspicuous epithelial strands in a fibrocellular background (hematoxylin-eosin,
original magnification3400).
Figure 4. Ameloblastic carcinoma showing perineural invasion of the inferior alveolar nerve (a named nerve) (hematoxylin-eosin, original
magnification340).
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possible staging have been suggested.1 Using data from the
National Cancer Institute’s SEER (Surveillance, Epidemiol-
ogy, and End Results) database for the period 1973–2011,
Agarwal et al2 and Lee et al3 showed that size was an
independent prognostic indicator with smaller tumor size
significantly associated with a better overall survival.
Patients with tumors greater than 41 mm were twice as
likely to die of disease as patients with smaller lesions.2 The
rationale for using both core and noncore is the need to use
both pathologic and imaging data to determine the lesion’s
dimensions, with the latter potentially not easily available to
the prosecting pathologist.
Histologic Tumor Type.—The gnathic bones give rise to
a variety of neoplasms, including odontogenic and bone/
cartilage forming tumors; however, this data set is designed
to report only the malignant odontogenic tumors (carcino-
mas as well as sarcoma) as classified according to the most
recent edition of the World Health Organization’s (WHO)
Classification of Head and Neck Tumours4 (Table). Bone and
cartilage forming tumors are classified using a different data
set.
Histologic Tumor Grade.—For primary intraosseous
squamous carcinoma, the conventional squamous cell
carcinoma grade is used.5,6 Although other malignant
odontogenic tumors are generally not graded, the pathol-
ogist can still comment on the extent of tissue changes (for
these non–squamous cell carcinoma tumors, histologic
tumor grade is a noncore item). This especially applies to
ameloblastic carcinoma, where there may be varying
degrees of cytologic atypia (Figure 1).
Necrosis.—Tumor necrosis is not only a tool to aid in
tumor grading, but also the presence of necrosis often helps
to confirm a diagnosis of malignancy in odontogenic tumors
in general (Figure 2). Thus, while large clinical series of
these rare tumors are not available, there is strong support
that reporting tumor necrosis aids in diagnosis, grade, and
tumor classification.7,8
Perineural Invasion.—Perineural invasion is included as
a generic descriptor that is considered to be relevant for all
types of malignant tumors (Figure 3). Note, however, that
the extensive perineural spread seen in sclerosing odonto-
genic carcinoma does not appear to be a poor prognostic
feature (Figures 4 and 5, A and B).9–11
Lymphovascular Invasion.—Lymphovascular invasion
is generally a feature seen in malignancy, and thus, it is
World Health Organization Classification
of Malignant Odontogenic Tumors
Descriptor ICD-O Codesa
Ameloblastic carcinoma 9270/3
Primary intraosseous carcinoma, NOS 9270/3
Sclerosing odontogenic carcinoma 9270/3
Clear cell odontogenic carcinoma 9341/3
Ghost cell odontogenic carcinoma 9302/3
Odontogenic carcinosarcoma 8980/3
Odontogenic sarcomas 9330/3
Abbreviation: NOS, not otherwise specified.
a The morphology codes are from the International Classification of
Diseases for Oncology (ICD-O). Behavior is coded /0 for benign
tumors; /1 for unspecified, borderline, or uncertain behavior; /2 for
carcinoma in situ and grade III intraepithelial neoplasia; and /3 for
malignant tumors.
Reproduced with permission from World Health Organization (WHO)/
International Agency for Research on Cancer (IARC).4
Figure 5. Perineural growth is a typical feature of sclerosing odontogenic carcinoma (A), highlighted by an S100 protein study (B) (hematoxylin-
eosin, original magnification3600 [A]; original magnification3600 [B]).
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included here, although data specific to malignant odonto-
genic tumors are not yet reported (Figure 6).
Margin Status.—Margin status is considered a key
prognostic factor. Clear margins are commonly achieved
only with a thin layer of normal tissue between the tumor
and the resection margin. It is therefore of crucial
importance to assess whether the excision has an adequate
margin around the entire lesion, since if there is focal
margin positivity, reoperation may be necessary.
The prognosis is worse when an incomplete excision is
located at the infratemporal fossa and/or base of skull and
thus, reporting the specific anatomic site of involved
margins must be clearly specified (Figure 7).
Noncore (Recommended) Elements
Extent of Invasion.—Extent of invasion is best assessed
by a combination of radiographic, macroscopic, and
microscopic features (Figure 8). Use of a diagram (Figure
9) is strongly recommended, as the pertinent anatomic
landmarks can be easily identified and assessed in the
embedding and sectioning protocol.
Ancillary Studies.—There are several immunohisto-
chemical and molecular studies that may be clinically
relevant,12 with some to have potential but unproven
therapeutic benefit. Examples include EWSR1 rearrange-
ments in clear cell odontogenic carcinoma and BRAF V600E
point mutation in ameloblastic carcinoma.13,14 Such tests
may also increase diagnostic certainty. Thus, if any of these
tests are performed, they should be recorded.
DISCUSSION
This data set is based almost exclusively on professional
judgement owing to the lack of high-quality evidence to
support individual data items. Malignant odontogenic
tumors are rare and published series are often not
homogeneous by tumor type, classification, stage, or
treatment, making conclusions about the value of individual
items difficult. In general, the tumors that show aggressive
histologic features are more likely to be associated with poor
survival, but this tumor group is characterized by unpre-
dictable behavior; low-grade tumors may recur or metasta-
size many years after excision. For all types, large size, local
recurrence, and metastasis are poor prognostic fea-
tures2,3,15,16 and outcomes are relatively poor after local
recurrence.17–19 Published mortality rates are generally
limited by short follow-up. Ameloblastic carcinomas appear
to carry a better prognosis than other tumor types for
reasons that are still unclear,2 although maxillary tumors
behave worse than mandibular neoplasms,20 with up to
one-third of maxillary tumors yielding lung metastases.
Odontogenic sarcomas are overall of low grade and tend to
locally recur rather than to metastasize, but are still
associated with significant mortality rates21–23 owing to local
involvement of vital structures.
There are no validated grading systems for odontogenic
tumors, although primary intraosseous squamous cell
carcinomas are graded by conventional squamous cell
carcinoma grading schemes, ostensibly showing some
value.5,6 Tumor necrosis is included as a histologic core
feature but is also considered useful in confirming a
diagnosis of malignancy in general. Perineural invasion is
an included element, although it must be emphasized that
in sclerosing odontogenic carcinoma, despite extensive
perineural spread, this carcinoma nevertheless carries a
relatively good prognosis.9,10,11
Margin status after surgical excision is thought to be the
key prognostic feature15,24–27 and the best evidence relates to
ameloblastic carcinoma,2,28 primary intraosseous carcino-
ma,5,17 and clear cell carcinoma.24 Surgical margin clearances
may be very small or inadequate and extension into soft
tissues beyond the periosteum is usually associated with a
significant risk of local recurrence. The prognosis is worse
when incomplete excision is seen at the infratemporal fossa
and/or base of skull and therefore the anatomic site of
involved margins must be clearly specified and marked on a
diagram (Figure 9) during macroscopic and microscopic
examination.
Tumor dimensions (size) and site are also important
prognostic features. Further, carcinomas arising in or limited
to cysts carry a better prognosis than those with widespread
infiltration.29
The role for adjuvant or salvage radiotherapy remains to
be defined. The literature does not provide useful informa-
tion on specific radiotherapy indications or the intent when
it has been used. Despite its use to locally control
Figure 6. Vascular invasion in ameloblastic carcinoma can be
highlighted by a CD31 immunohistochemistry study, with tumor filling
the endothelial lined space (original magnification3400).
Figure 7. A positive margin in ghost cell odontogenic carcinoma
(hematoxylin-eosin, original magnification3100).
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incompletely excised malignant odontogenic tumors, its
value appears limited,24,25 although it has been supported in
some large series2 and is usually considered most effective
as part of a multimodality treatment approach. This is true
particularly for maxillary lesions in which vital structures
may prevent surgical management.
Ancillary studies still play a relatively limited role12–14; they
are sometimes helpful in diagnosis, while molecular findings
may help to guide targeted therapeutic options. However,
availability and cost constraints limit widespread adoption,
especially in developing nations.
Finally, while ameloblastomas are benign, they often
require an oncologic (surgical) approach to management,
and thus, the panel recommends discussion of ameloblas-
tomas at a multidisciplinary team meeting (tumor board) to
ensure optimal management. Furthermore, this tumor
would also benefit from a standardized reporting data set.
While this data set was prepared for malignancies, the panel
also strongly advocates its use for ameloblastoma.
The authors would like to express their appreciation to the
sponsoring societies and organizations and give special thanks to
Fleur Webster and Hannah B. Canlas for their exceptional
organizational and editing contributions. The views expressed are
those of the authors solely.
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